Literature DB >> 30195616

Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.

Christopher T Rentsch1, Emily J Cartwright2, Neel R Gandhi3, Sheldon T Brown4, Maria C Rodriguez-Barradas5, Matthew Bidwell Goetz6, Vincent C Marconi7, Cynthia L Gibert8, Vincent Lo Re9, David A Fiellin10, Amy C Justice11, Janet P Tate12.   

Abstract

PURPOSE: Pharmacoepidemiologic studies using electronic health record data could serve an important role in assessing safety and effectiveness of direct-acting antiviral therapy for chronic hepatitis C virus (HCV) infection, but the validity of these data needs to be determined. We evaluated the accuracy of pharmacy fill records in the national Veterans Health Administration (VA) Corporate Data Warehouse (CDW) as compared to facility-level electronic health record.
METHODS: Patients prescribed a direct-acting antiviral regimen at five VA sites between 2014 and 2016 were randomly selected and reviewed. A random sample of patients with chronic HCV infection without evidence of HCV treatment during the study period also underwent chart review. We calculated positive predictive value and negative predictive value overall and by site.
RESULTS: Of the 501 patients who received a total of 2416 prescriptions, 494 were validated using data extracted from CDW 6 months after the study period, yielding a positive predictive value of 98.6% (95% confidence interval, 97.6%-99.6%). Of the 100 patients with chronic HCV infection without prescriptions for HCV treatment, 99 were confirmed not to have received antiviral treatment (negative predictive value, 99.0%; 95% confidence interval, 97.1%-100%).
CONCLUSIONS: These findings provide assurance to researchers who use national VA CDW data for retrospective cohort studies that the CDW contains accurate information on HCV therapies in the modern treatment era.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antivirals; Direct-acting antiviral; Hepatitis C; Observational data; Pharmacy; Validation

Mesh:

Substances:

Year:  2018        PMID: 30195616      PMCID: PMC6318448          DOI: 10.1016/j.annepidem.2018.08.007

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  10 in total

1.  VHA Corporate Data Warehouse height and weight data: opportunities and challenges for health services research.

Authors:  Polly Hitchcock Noël; Laurel A Copeland; Ruth A Perrin; A Elizabeth Lancaster; Mary Jo Pugh; Chen-Pin Wang; Mary J Bollinger; Helen P Hazuda
Journal:  J Rehabil Res Dev       Date:  2010

2.  Elevated prevalence of hepatitis C infection in users of United States veterans medical centers.

Authors:  Jason A Dominitz; Edward J Boyko; Thomas D Koepsell; Patrick J Heagerty; Charles Maynard; Jennifer L Sporleder; Andrew Stenhouse; Mitchel A Kling; William Hrushesky; Charles Zeilman; Stephen Sontag; Nikunj Shah; Fernando Ona; Bhupinder Anand; Marc Subik; Thomas F Imperiale; Samer Nakhle; Sam B Ho; Edmund J Bini; Bruce Lockhart; Jawad Ahmad; Anna Sasaki; Brian van der Linden; Doris Toro; Jaime Martinez-Souss; Vivek Huilgol; Seth Eisen; Keith A Young
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

3.  Evaluating the Veterans Choice Program: Lessons for Developing a High-performing Integrated Network.

Authors:  Kristin M Mattocks; Baligh Yehia
Journal:  Med Care       Date:  2017-07       Impact factor: 2.983

4.  Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

Authors:  Diana Gritsenko; Gregory Hughes
Journal:  P T       Date:  2015-04

5.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Authors:  Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

6.  Veterans Aging Cohort Study (VACS): Overview and description.

Authors:  Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant
Journal:  Med Care       Date:  2006-08       Impact factor: 2.983

7.  Development and verification of a "virtual" cohort using the National VA Health Information System.

Authors:  Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice
Journal:  Med Care       Date:  2006-08       Impact factor: 2.983

8.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

10.  Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).

Authors:  Eric Lawitz; Gary Matusow; Edwin DeJesus; Eric M Yoshida; Franco Felizarta; Reem Ghalib; Eliot Godofsky; Robert W Herring; Gary Poleynard; Aasim Sheikh; Hillel Tobias; Marcelo Kugelmas; Ronald Kalmeijer; Monika Peeters; Oliver Lenz; Bart Fevery; Guy De La Rosa; Jane Scott; Rekha Sinha; James Witek
Journal:  Hepatology       Date:  2016-02-19       Impact factor: 17.425

  10 in total
  1 in total

1.  Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

Authors:  Jessie Torgersen; Craig W Newcomb; Dena M Carbonari; Christopher T Rentsch; Lesley S Park; Alyssa Mezochow; Rajni L Mehta; Lynn Buchwalder; Janet P Tate; Norbert Bräu; Debika Bhattacharya; Joseph K Lim; Tamar H Taddei; Amy C Justice; Vincent Lo Re
Journal:  J Hepatol       Date:  2021-07-29       Impact factor: 30.083

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.